Clinical trial
A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma
NCT01176461 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 4, 2010
- Completion date
- December 12, 2016
- Enrollment
- 127 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
melanoma (skin)